- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
MR-guided ultrasound relieves bone metastasis pain
High-intensity focused ultrasound (HIFU) has shown promise as a pain management strategy in patients with bone metastases for whom other treatments are ineffective, according to researchers at the Sheba Medical Center in Israel (Ann Oncol 2007;18:163-167).
High-intensity focused ultrasound (HIFU) has shown promise as a pain management strategy in patients with bone metastases for whom other treatments are ineffective, according to researchers at the Sheba Medical Center in Israel (Ann Oncol 2007;18:163-167).
The goal of treatment for bone metastases is to relieve pain and reduce the risk of fracture. Treatment may consist of surgery, radiation therapy, pain medications, and/or bisphosphonate drugs.
In the study, 10 patients reported prolonged improvement in pain and/or a reduced dose of pain medication following MR-guided ultrasound ablation of bone metastases. One other patient found the MR-guided HIFU procedure too uncomfortable to complete treatment.
MR-guided HIFU is approved in the U.S. only for uterine fibroids, but researchers are investigating applications in breast, prostate, and brain tumors.
FDA Grants Expanded 510(k) Clearance for Xenoview 3T MRI Chest Coil in GE HealthCare MRI Platforms
November 21st 2024Utilized in conjunction with hyperpolarized Xenon-129 for the assessment of lung ventilation, the chest coil can now be employed in the Signa Premier and Discovery MR750 3T MRI systems.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
Ultrasound Device Garners FDA De Novo Nod for Kidney Stone Clearance
November 14th 2024Emerging research demonstrated that the Stone Clear device, which facilitates post-lithotripsy clearance of kidney stone fragments, led to a 70 percent lower risk of relapse in comparison to observation in a control group.
